very elderly is sparse. Objective: To retrospectively compare characterization and approach of NSCLC patients (pts) aged 70-79 and 80 years. Method: We performed a retrospective analysis of 297 adult NSCLC pts who registered and initiated NSCLC management in our Pulmonology Oncology Unit from January 2013 to December 2016 corresponding to 38.2% of all NSCLC patients (n¼778). Demographic data and lung cancer management were analyzed. Results: Pts were categorized as elderly (n¼211, 71.0%) and very elderly (n¼86, 29.0%). Very elderly pts had worse ECOG PS (p¼0.03), higher Charlson-age comorbidity index (p<0.001) and the majority had stage IV cancer (66.3%, p¼0.04). First management option in very elderly pts was chemotherapy (CTX) (30.2%, p¼0.37) and in elderly pts was multimodal therapy (30.3%, p¼<0.001). First-line targeted (EGFR or ALKpositive) and support therapy were more common in the very elderly (23.6%, p¼0.001; 17.4% p¼0.002, respectively). Curative radiation or surgery rates did not differ between groups. Reasons for premature first-line CTX stop, toxicity and hospitalization did not differ. Death rate (69.7% vs. 63.5% for very elderly and elderly, respectively) and mean survival since diagnosis (11.5 months vs. 11.6 months for very elderly and elderly, respectively) did not differ. Background: This study aimed to explore the effect of lysophosphatidylcholine acyltransferase 1(LPCAT1), a cytosolic enzyme, on lung cancer and brain metastasis (BM) of lung cancer both in vivo and in vitro. Method: Small hairpin RNA (shRNA) specific for LPCAT1 was used to knockdown the expression of LPCAT1 both in HCC827 and PC-9 nonesmall cell lung cancer (NSCLC) cell lines. CCK-8, transwell migration and invasion assays in vitro was used to examine the effect of LPCAT1 on cell proliferation, migration and invasion. GSEA analysis was performed to characterize signaling pathways associated with LPCAT1. Western blotting and RT-PCR were used to detect the expression of LPCAT1 and PI3K/AKT/MYC signal pathway. Immunohistochemical (IHC) and RNA-Seq analysis were used to detect the expression of LPCAT1 in situ tissues of lung cancer patients with or without BM and normal human lung tissues. Xenograft model were used to examine the effect of LPCAT1 on cell proliferation. The data about clinical stages of LUAD patients was obtained from, an online database, Oncomine. Results: LPCAT1 was up-regulated in NSCLC tissues and cell lines and it's essential for the proliferation, migration and invasion of NSCLC in vitro. LPCAT1 amplification status was correlated with MYC-activated geneset by GSEA analysis. What's more, down regulating of LPCAT1 attenuates the PI3K/AKT signaling pathway in part by targeting MYC. The expression of LPCAT1 in human lung tissues was highest in lung tumor tissues from lung cancer patients with BM, followed in tissues from lung cancer patients without B and the lowest in normal human lung tissues. LPCAT1 promoted tumorigenesis in vivo and was associated with poor clinical outcomes. Conclusion: LPCAT1 promoted NSCLC proliferation, metastasis and tumorigenesis in vitro and in vivo, More importantly we uncovered that this effect of LPCAT1 was partially via the PI3K/AKT/MYC pathway.
Background: This study aimed to explore the effect of lysophosphatidylcholine acyltransferase 1(LPCAT1), a cytosolic enzyme, on lung cancer and brain metastasis (BM) of lung cancer both in vivo and in vitro. Method: Small hairpin RNA (shRNA) specific for LPCAT1 was used to knockdown the expression of LPCAT1 both in HCC827 and PC-9 nonesmall cell lung cancer (NSCLC) cell lines. CCK-8, transwell migration and invasion assays in vitro was used to examine the effect of LPCAT1 on cell proliferation, migration and invasion. GSEA analysis was performed to characterize signaling pathways associated with LPCAT1. Western blotting and RT-PCR were used to detect the expression of LPCAT1 and PI3K/AKT/MYC signal pathway. Immunohistochemical (IHC) and RNA-Seq analysis were used to detect the expression of LPCAT1 in situ tissues of lung cancer patients with or without BM and normal human lung tissues. Xenograft model were used to examine the effect of LPCAT1 on cell proliferation. The data about clinical stages of LUAD patients was obtained from, an online database, Oncomine. Results: LPCAT1 was up-regulated in NSCLC tissues and cell lines and it's essential for the proliferation, migration and invasion of NSCLC in vitro. LPCAT1 amplification status was correlated with MYC-activated geneset by GSEA analysis. What's more, down regulating of LPCAT1 attenuates the PI3K/AKT signaling pathway in part by targeting MYC. The expression of LPCAT1 in human lung tissues was highest in lung tumor tissues from lung cancer patients with BM, followed in tissues from lung cancer patients without B and the lowest in normal human lung tissues. LPCAT1 promoted tumorigenesis in vivo and was associated with poor clinical outcomes. Conclusion: LPCAT1 promoted NSCLC proliferation, metastasis and tumorigenesis in vitro and in vivo, More importantly we uncovered that this effect of LPCAT1 was partially via the PI3K/AKT/MYC pathway. Background: Several studies show that those patients with a PD-L1 expression have greater benefits in the response rate, PFS and OS. In our institution, in 2014, we conducted a study in which it was possible to show that the presence of infiltrating lymphocytes of the tumor is associated with a longer PFS and OS. In another study, we showed that the presence of lymphocyte infiltration, in patients with breast cancer had higher survival; that is why in this study we want to analyze the relationship between the expression of the PD-L1 and the tils. Objective: The objective of this study is to analyze the relationship between the expression of PD-L1 and the intratumoral and stromal TILS in patients with advanced lung cancer and the overall survival of these patients Method: Retrospective and analytical study in which patients with advance NSCLC from Instituto Oncológico de Córdoba were studied. The tumor samples have been analyzed. Immunohistochemistry will be the procedure used to evaluate the expression of PD-L1 and intratumoral and stromal lymphocytes. The survival analysis will be evaluated by the Kaplan-Meier method and by the log-rank test. . Patients who presented TILSi had a median OS of 11.4 m vs 8.7 m in those without TILSi, these differences were statistically significant and were related to the expression of PD-L1 p: (0.01 vs 0.4) respectively. Those that evidenced TILs vs absence of TILs. the OS was 11.7 m vs 7.5 m; these differences were significant and were also related to the expression of PD-L1 (0.03
